Why working prototypes stall before the market: medtech's lesson

A working prototype is not a product. That is the central claim of an analysis published by Research & Development World, which draws on medical device development to explain why promising technologies routinely stall on the path to market — and what R&D managers in any sector can take from that pattern.

The argument starts from a simple observation. Across R&D, translating a promising discovery into something that ships requires three separate achievements, and only one of them is technical. A team must find someone who actually needs the technology. It must find a practical way to deliver it. And it must find a business model that can sustain it. A prototype answers none of those questions directly; it only proves that the underlying idea can work under controlled conditions.

Medical device development, the analysis suggests, makes this gap unusually visible. The stakes are especially high there — the piece points to this pressure without yet detailing the specific cases — because devices must pass from bench evidence to regulatory scrutiny, clinical use, and reimbursement before anyone can call them products. Each of those transitions can kill a program that looked healthy in the lab.

What separates a prototype from a product?

The mechanism is worth taking apart. A prototype is validated against a question the researchers themselves chose: does this function as designed? A product has to survive questions chosen by others — does a clinician want it, does a hospital buy it, does a payer reimburse it, does a regulator clear it? Those are not harder versions of the engineering question. They are different questions, with different evidence standards and different decision-makers.

This is why the failure mode is so common and so misleading. A program can clear every technical milestone and still stall, because the technical milestones were never the binding constraint. The binding constraint sat elsewhere: in demand that was assumed rather than demonstrated, in a delivery pathway that was never costed, or in an economics that no one modeled until late.

How should portfolio managers read this?

The practical implication for R&D management concerns where scrutiny goes, and when. If the three requirements — need, delivery, business model — are genuinely separate, then gate reviews that test only technical readiness will systematically overestimate a portfolio's distance from market. The analysis frames translation as a search problem: someone has to go find the user, the delivery route, and the revenue logic. None of these announces itself.

That reframing has budget consequences. Discovery work and translation work compete for the same funding in most organizations, and translation work — user research, delivery pilots, business-model testing — often looks less prestigious than further technical refinement. Teams respond rationally to that incentive by polishing the prototype rather than interrogating the market. The stall point, in other words, is frequently an allocation decision made years earlier.

Why medtech makes the pattern legible

Medical devices sharpen the lesson because their translation path is formalized. Where a consumer product might fail quietly in the market, a device fails visibly at named checkpoints — evidence packages, review bodies, procurement processes. The checkpoints force the three questions into the open. Sectors with softer checkpoints can hide the same unresolved issues until launch, which makes medtech a useful teaching case even for teams outside health.

The comparison is instructive in one concrete way: a device that works in a lab is roughly analogous to a drug candidate that works in cell culture. Both demonstrate mechanism, neither demonstrates use. The pharma industry built an entire staged-development discipline around that distinction. Device development, and by extension much of R&D, is still learning it.

What the analysis does not claim

It is worth being precise about scope. The published excerpt does not offer failure statistics, named case studies, or quantified translation rates. It offers a framework. Claims about how often technologies stall, and why specific programs died, would require evidence the piece has not yet shown. Readers should treat the three-requirement structure as an analytical lens, not as a measured result.

That caution matters for how managers use the argument. The framework justifies asking harder questions at existing gates — who validated the need, what does delivery cost, where does revenue come from — but it does not by itself justify restructuring a portfolio. Applied honestly, it converts assumptions into testable items on an agenda.

The full analysis, published at Research & Development World, extends the argument into the specifics of the medtech cases. For R&D leaders, the immediate takeaway is structural: translation is not the last phase of engineering but a parallel search for need, delivery, and economics, and programs that defer that search are the ones that stall.